Due to the high response rate, rapid response kinetics, and favorable drug safety profile in metastatic and adjuvant settings, targeted therapy with BRAF and MEK inhibitors may also provide an effective neoadjuvant treatment in melanoma patients [28,29]. Here, BRAF is linked to melanoma.